Suspension of trading
Valuation Exact Sciences Corporation
Stocks
EXAS
US30063P1057
Biotechnology & Medical Research
|
Delayed
Nasdaq
20:00:00 20/03/2026 GMT
|
5-day change | 1st Jan Change | ||
| 104.91 USD | +0.95% |
|
-.--% | +3.30% |
| 03-25 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index | CI |
| 03-25 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index | CI |
Company Valuation: Exact Sciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 21,070 | 13,412 | 8,797 | 13,379 | 10,399 | 19,273 |
| Change | - | -36.35% | -34.41% | 52.09% | -22.27% | 85.32% |
| Enterprise Value (EV) 1 | 20,981 | 14,782 | 10,623 | 15,168 | 12,137 | 20,843 |
| Change | - | -29.55% | -28.14% | 42.79% | -19.98% | 71.73% |
| P/E | -23.6x | -22.4x | -14x | -65.3x | -10.1x | -92.2x |
| PBR | 7.48x | 3.99x | 2.89x | 4.27x | 4.34x | 8.07x |
| PEG | - | 0.6x | -8.18x | 1x | -0x | 1.1x |
| Capitalization / Revenue | 14.1x | 7.59x | 4.22x | 5.35x | 3.77x | 5.94x |
| EV / Revenue | 14.1x | 8.37x | 5.1x | 6.07x | 4.4x | 6.42x |
| EV / EBITDA | -50.1x | -29.1x | -25.1x | -148x | 526x | 292x |
| EV / EBIT | -36x | -21.5x | -17.1x | -49.1x | -63.3x | -139x |
| EV / FCF | -141x | 1,095x | -39.7x | 165x | 216x | 73.9x |
| FCF Yield | -0.71% | 0.09% | -2.52% | 0.61% | 0.46% | 1.35% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -5.614 | -3.476 | -3.536 | -1.133 | -5.59 | -1.102 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1,491 | 1,767 | 2,084 | 2,500 | 2,759 | 3,247 |
| EBITDA 1 | -418.7 | -508.2 | -423.4 | -102.2 | 23.07 | 71.46 |
| EBIT 1 | -582 | -688.5 | -620.9 | -308.8 | -191.8 | -150.1 |
| Net income 1 | -848.5 | -595.6 | -623.5 | -204.1 | -1,029 | -207.9 |
| Net Debt 1 | -88.84 | 1,370 | 1,825 | 1,789 | 1,738 | 1,570 |
| Reference price 2 | 132.49 | 77.83 | 49.51 | 73.98 | 56.19 | 101.56 |
| Nbr of stocks (in thousands) | 159,030 | 172,319 | 177,684 | 180,850 | 185,076 | 189,766 |
| Announcement Date | 16/02/21 | 22/02/22 | 21/02/23 | 21/02/24 | 19/02/25 | 13/02/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 20.03B | |
| -44.48x | 12.99x | 835.01x | -.--% | 3.87B | |
| -17.04x | 8.52x | -16.98x | -.--% | 3.69B | |
| 37.91x | 4.75x | 17.42x | -.--% | 3.38B | |
| 23.61x | - | - | - | 2.59B | |
| 134.52x | - | - | - | 2.08B | |
| -7.51x | - | - | - | 1.59B | |
| 16.22x | 1.98x | 6.93x | 3.65% | 1.07B | |
| -21.89x | 5.18x | 32.42x | -.--% | 1B | |
| Average | 15.17x | 6.68x | 174.96x | 0.73% | 4.36B | |
| Weighted average by Cap. | 11.28x | 8.07x | 251.12x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EXAS Stock
- Valuation Exact Sciences Corporation
Select your edition
All financial news and data tailored to specific country editions
